Introduction
The ®broblast growth factors (FGFs) form a family of at least ten growth regulatory proteins that share 35 ± 50% amino acid sequence identity and induce proliferation and dierentiation in a wide range of cells of epithelial, mesodermal and neuroectodermal origin (Basilico and Moscatelli 1992; Tanaka et al., 1992; Miyamoto et al., 1993; Yamasaki et al., 1996) . FGF8 was originally isolated from the conditioned medium of an androgen dependent mouse mammary carcinoma line (SC-3) as an androgen induced growth factor (AIGF) and was later assigned as a member of the ®broblast growth factor family on the basis of structural similarity (Tanaka et al., 1992 ). FGF8 appears to have an important role in embryogenesis. It is expressed in several areas of the developing mouse and may play a critical role in the development of the face, limb and central nervous system (Crossley and Martin 1995; MacArthur et al., 1995c; Crossley et al., 1996a, b) . Little expression of FGF8 is found in adult mouse tissues with comparatively low amounts detected only in the ovaries and testes (MacArthur et al., 1995a; Lorenzi et al., 1995) . FGF8 was identi®ed as an oncogene on the basis of overexpression of FGF8 in NIH3T3 cells leading to focus formation, growth in soft agar and tumour formation in nude mice (Kouhara et al., 1994; MacArthur et al., 1995b) . FGF8 was subsequently found to act as a protooncogene co-operating with Wnt 1 in mouse mammary tumorigenesis (MacArthur et al., 1995a) .
The structure of the FGF8 gene is more complex than the other members of this family. Most FGFs are encoded by three exons but in the case of FGF8 there are at least four exons corresponding to the usual ®rst exon of the other genes. Alternative splicing gives rise to potentially eight dierent protein isoforms in the mouse diering at the amino terminus but remaining identical at the carboxyl end Martin 1995, MacArthur et al., 1995c) . In man, only four of these forms will be possible due to a stop codon in exon 1B (Gemel et al., 1996) . The biological signi®cance of these forms is, as yet, unknown but there is already evidence that they possess dierent transforming potential with FGF8b having the highest transforming activity and widest receptor binding properties (MacArthur et al., 1995b,c; Ghosh et al., 1996) .
The response of cells to FGFs is mediated through formation of a ternary complex of growth factor, proteoglycan and high-anity receptor (Yayon et al., 1991; Klagsbrun and Baird, 1991; Rapraeger et al., 1991; Kan et al., 1993) . The four high anity ®broblast growth factor receptors are tyrosine kinase receptors, encoded by four distinct genes. They consist of an extracellular ligand binding domain comprising three immunoglobulin-like domains, a transmembrane domain and an intracellular split kinase domain which is involved in signal transduction. They share a high amino-acid sequence homology and are characterized by a large number of variant forms generated by alternative mRNA splicing (Jaye et al., 1992; Hou et al., 1991) . One kind of splice variant involves the use of alternative exons encoding the carboxyl-terminal half of the third immunoglobulin domain. This form of splice variation occurs for FGFR1, FGFR2 and FGFR3 so that IIIb and IIIc forms of these receptors have very dierent ligand binding properties (Miki et al., 1992; Werner et al., 1992; Chellaiah et al., 1994) . These two isoforms appear to be expressed in a mutually exclusive fashion with cells of mesenchymal origin expressing IIIc variants of FGFR2 and FGFR3 whereas epithelial cells express the IIIb isoform (Pekonen et al., 1993; Savagner et al., 1994) . The interaction of several splice variants of FGF8 with high anity receptors has been investigated (MacArthur et al., 1995c) . FGF8c activates FGFR3-IIIc and FGFR4 while FGF8b activates FGFR2-IIIc as well as FGFR3-IIIc and FGFR4. There is some debate as to whether FGFR1 may be a receptor for FGF8 since a splice variant of FGFR1 has been shown to bind FGF8 (Kouhara et al., 1994) .
We have been interested in assessing the role of ®broblast growth factors in the normal and malignant human breast. Previous work has shown that FGF1 and FGF2 are present in large amounts in the normal breast, implying roles for these growth factors in maintaining the structure of the normal ducts (Gomm et al., 1991 Coope et al., 1997) . In breast cancer, there is a decrease in the amount of FGF1 and FGF2 present in breast tissue (Bansal et al., 1995; Yiangou et al., 1997a) . However, in the case of FGF1, there is evidence for some remaining in a more functionally available form in breast cancers (Smith et al., 1994; Coope et al., 1997) . FGF7 is found in similar amount in both malignant and non-malignant breast tissue. It is produced by stromal ®broblasts and acts via the KGF receptor (FGFR2-IIIb) on epithelial cells . Other studies show no expression of FGF3 and FGF4 in human breast cancers but expression of all other FGFs in at least a small proportion of breast cancers (Penault-Llorca et al., 1995) . All four of the FGFRs are expressed to some degree in breast cell lines (Ron et al., 1993; McLeskey et al., 1994; Johnston et al., 1995b) . Although ampli®cation of the fgfr4 gene has been found in 10% of breast cancers, we have previously shown that equivalent levels of FGFR4 are present in the epithelial cells of malignant and non-malignant breast sections (Jaakkola et al., 1993; Coope et al., 1997) . In the case of FGFR1, signi®cant changes in the isoform of FGFR1 expressed occur on malignant transformation although the level of expression appears to stay the same (Yiangou et al., 1997b; Coope et al., 1997) .
Previous work has shown that FGF8 is expressed by prostate and breast cancer cell lines (Schmitt et al., 1996; Tanaka et al., 1995) . An involvement in malignant prostate disease has been demonstrated since FGF8 is detected in prostatic cancers, but not in benign prostatic hypertrophy (Leung et al., 1996) . Following on from these observations, we have studied the occurrence of FGF8 mRNA in non-malignant breast tissue and in breast cancers. Our results show that FGF8 is present signi®cantly more often in malignant tumours and at a higher level. Analysis of cell lines and puri®ed populations of normal breast cell populations showed that the highest levels of FGF8 mRNA expression were found in malignant epithelial cells and this has been con®rmed using in situ hybridization. We have also investigated the occurrence of receptors for FGF8b in breast cancer. FGFR2-IIIc is expressed in cells of mesenchymal origin and is not present in breast epithelial cells . Similarly our own unpublished results and others have shown that FGFR3-IIIc is not found in breast epithelial cells (Savagner et al., 1994) . We have however detected FGFR4 and FGFR1 in breast cancer cells opening the possibility of an autocrine loop in breast epithelial cells.
Results

Expression of FGF8 mRNA in breast tissues
A panel of 92 human breast tissues consisting of 68 cancers and 24 non-malignant samples was used in this study ( Table 1) . The panel contains a representative cross-section of breast tumours. RNA was extracted from the tissue samples and was used in a semi quantitative RT ± PCR analysis to determine the expression of FGF8 isoforms in the breast. Actin and FGF8 were ampli®ed using 24 and 32 cycles of ampli®cation respectively so that reactions were in a linear growth phase (as seen in Figure 1c ) and a ratio of FGF8/actin gave a semi-quantitative value for FGF8 expression. The primers used to amplify FGF8 were chosen from regions of FGF8 conserved in all isoforms so that all variants of FGF8 could be ampli®ed ( Figure  1a ). An example of results is shown in Figure 1b . All samples except for controls showed the expected 316 base pair product for actin and when FGF8 was ampli®ed, a single product of 549 bp was detected in some tissues. This indicates that only one form of FGF8 appears to be present in the human breast and the size of the band corresponds to that expected for FGF8b. FGF8 was not found in all the tissues examined but signi®cantly more malignant samples were found to express it using the w 2 test. We found that 33% (eight out 24) of the non malignant samples were FGF8 positive compared with 68% (42 out of 68) of the cancers (P=0.019). The mean level of FGF8 was also found to be higher in the malignant tissues compared to the non-malignant tissues ( Figure 2 ). Mean values of 2.6 and 8.9 were found for non-malignant and malignant tissues and this represents a signi®cant dierence by the Mann ± Whitney U-test (P=0.031). Similar results were obtained when a selection of the PCR reactions were repeated using FGF8 primers and GAPDH primers in the same tube. Table 1 shows the relationship between clinical parameters and the level of FGF8 mRNA detected in Figure 1 Detection of FGF8 mRNA by RT ± PCR. (a) Shows the exon structure of FGF8 human isoforms and the positions of PCR primers used to amplify all isoforms of FGF8 and detect the product by Southern blotting. Dark exons are those present in all FGF8 transcripts while lighter parts of exons are present in only some transcripts. (b) Shows examples of RT ± PCR products ampli®ed from breast tissues after running on a 2% agarose gel and detection of bands by Southern blotting. Section A shows the detection of FGF8 PCR product whereas section B shows the detection of actin PCR product for the same samples. Lane 1 contains PCR product from a plasmid preparation of FGF8b, lane 5 contains a negative control where no RNA was added to the PCR reaction and lanes 2 ± 4 and 6 ± 10 contain PCR products after ampli®cation of RNA extracted from dierent malignant breast tissues. (c) Shows the amount of actin and FGF8 PCR product produced after dierent numbers of cycles demonstrating that the number of PCR cycles for the standard reaction lies in the logarithmic phase b a FGF8 in human breast cancer SK Marsh et al
samples. There appears to be no correlation between the level of FGF8 mRNA and menopausal status, nodal status or estrogen receptor status, with mean values of FGF8 mRNA expression being very similar in each group and no statistical signi®cance between groups.
Expression of FGF8 in breast cell lines and isolated cell preparations
We were interested in determining which cells within the tissues samples were expressing FGF8. We used populations of normal epithelial and myoepithelial cells puri®ed immuno-magnetically from reduction mammoplasty tissue to determine FGF8 expression in normal breast tissue using the same RT ± PCR method. Again only a single band consistent with FGF8b expression was detected. The expression levels seen in epithelial cells and myoepithelial cells from reduction mammoplasty tissue were both very low (Figure 3 ). We used a panel of breast cancer cell lines to ®nd whether the transformed epithelial cells express FGF8 (Figure 3) . Many of the breast cancer cells lines (ZR-75-1, MCF7, T47D) showed very low levels of FGF8 expression similar to that seen in the normal epithelial cells. However the level of expression seen in some of the breast cancer cells lines (PMC42, SKBRIII, MDA-MB-415) was substantially higher than that found in the non-malignant epithelial cells suggesting that overexpression of FGF8 may occur in a proportion of breast cancer cells. In all the breast cell lines investigated, only one isoform of FGF8 was detected.
In situ hybridization
In situ hybridization was used to con®rm the cellular expression of FGF8. Paran sections of breast cancers were probed with full length sense and anti-sense riboprobes for FGF8. Signals were only observed with the antisense FGF8 probe, all controls being negative (Figure 4 ). There was correlation between the RT ± PCR results and in situ hybridization results since eight samples positive for FGF8 by RT ± PCR gave staining by in situ hybridization whereas ®ve further samples showed no FGF8 expression by RT ± PCR and in situ hybridization. All labelling appeared to be in malignant epithelial cells with no signi®cant labelling observed in stromal cells. Para®n sections of non-malignant breast showed a low level of FGF8 expression (results not shown). Therefore FGF8 appears to be a predominantly epithelial expressed growth factor in the human breast. Figure 2 Scattergram comparing expression levels of FGF8 mRNA in malignant and non-malignant breast tissues. RT ± PCR was used to amplify FGF8 and actin mRNA from malignant and non-malignant breast tissue samples. After running on a 2% agarose gel and detection of bands by Southern blotting, a phosphoimager was used to quantify the level of expression. The level of expression shown on the x-axis is presented in arbitrary units as the FGF8 measurement divided by the actin measurement which should be constant in all samples so that results are corrected for variation in the eciency of the RNA preparation and RT reaction Receptor expression in breast cancer cells One group has shown that three ®broblast growth factor receptors (FGFR2c, FGFR3c and FGFR4) bind to FGF8b (Ornitz et al., 1996) . However, a separate report indicated that FGF8 can bind to an isoform of FGFR1 (Kouhara et al., 1994) . FGFR2IIIc is expressed in breast ®broblasts but not in epithelial cells Werner et al., 1992) . Our results (unpublished) show that several breast cancer cell lines express FGFR3-IIIb but not FGFR3-IIIc and Scotet and Houssaint (1995) reported that MCF7 and ZR-75 breast cancer cell lines express only the IIIb form. FGFR4 and possibly FGFR1 are candidates for receptors for FGF8 which could be involved in an autocrine loop in malignant breast epithelial cells. We have investigated the expression of FGFR4 mRNA in malignant and nonmalignant human breast tissues using semi-quantitative RT ± PCR. Figure 5 shows that very similar levels of FGFR4 mRNA were found in malignant and nonmalignant tissue samples implying that the level of FGFR4 present in malignant and non-malignant epithelial cells is likely to be very similar. No statistically signi®cant dierence could be detected using the Mann ± Whitney U-test. This is in agreement with immunohistochemical staining of human breast tissues where an antibody against FGFR-4 showed staining of epithelial and myoepithelial cells in normal samples and staining was retained at similar levels in malignant epithelial cells .
Discussion
In this study we have examined the expression of FGF8 mRNA in malignant and non malignant human breast tissue using a semi-quantitative RT ± PCR method. We ®nd more tissues expressing FGF8 and at higher levels in malignant tissues. In situ hybridization and analysis of cell lines and puri®ed populations of cells from reduction mammoplasty tissue show that FGF8 is expressed in epithelial cells and breast cancer cells. Of the known high anity receptors for FGF8, FGFR4 (and possibly FGFR1) are present in epithelial cells and we ®nd equivalent levels of FGFR4 in malignant and non-malignant breast cancers. We propose that FGF8 will produce autocrine stimulation of breast cancer cells which could eect their malignancy.
The FGF8 gene structure is more complex than that for the other members of the FGF family with dierential splicing mechanisms lead to the possibility of eight dierent variants in the mouse (Crossley and Martin, 1995) . Prostatic carcinoma cell lines were found to contain FGF8a, FGF8b and FGF8e although FGF8b was the predominant form (Ghosh et al., 1996) . Despite the potential presence of multiple splice variants of FGF8, we have detected only one isoform of FGF8 in our studies. In experiments investigating the ability of FGF8 isoforms to cause focus formation or tumour formation in nude mice using NIH3T3 cells overexpressing FGF8 isoforms, FGF8b was shown to have the greatest transforming ability, probably due to its ability to bind to a larger group of receptors (MacArthur et al., 1995b) .
We have found that FGF8 is present in statistically more malignant than non-malignant tumours (P=0.019), however 33% of women in the normal category still showed FGF8 expression albeit at low levels. This is in contrast to expression in the mouse where FGF8 was detected in ovary and testis but not in normal mammary gland (MacArthur et al., 1995a) . It is possible that FGF8 expression is overstated in this study due to the use of RT ± PCR to measure FGF8 mRNA levels. This is a very sensitive technique and very low levels of transcript which may not be translated into protein can be detected . A second cause of higher exaggerating the amount of FGF8 mRNA present in normal breast tissue is the use of adjacent normal tissues as part of the non-malignant complement, which may contain some malignant cells. However, we found that reduction mammoplasty tissue also contained FGF8 mRNA implying that malignancy is not the only cause of FGF8 expression. FGF8 is an androgen-induced growth factor and steroid hormone responsive tissues appear to be the main sites of expression of FGF8 in the adult (Tanaka et al., 1992; Payson et al., 1996) . Subsequent experiments have shown that FGF8 expression is induced in the breast carcinoma cell line MDA-MB-231 by DHT (Payson et al., 1996) . The expression of FGF8 in a third of normal mammary glands tested could be due to elevated steroid hormone levels in these women.
An examination of FGF8 mRNA expression in breast cell lines, puri®ed populations of cells from reduction mammoplasty tissue and using in situ hybridization on breast cancer sections has shown Figure 5 Expression of FGFR4 mRNA in breast tissues. RT ± PCR was used to amplify FGFR4 and actin mRNA from malignant and non-malignant breast tissue samples. After running on a 2% agarose gel and detection of bands by Southern blotting, a phosphoimager was used to quantify the level of expression. The level of expression shown on the x-axis is presented in arbitrary units as the FGFR4 measurement divided by the actin measurement which should be constant in all samples so that results are corrected for variation in the eciency of the RNA preparation and RT reaction that epithelial cells are the main source of FGF8. This is consistent with the distribution of FGF8 in other systems. In normal and malignant prostate, FGF8 expression was found in epithelial cells but not in stromal or endothelial cells using in situ hybridization (Leung et al., 1996) . Four receptors have been shown to bind to FGF8, namely FGFR2-IIIc, FGFR3-IIIc, FGFR4 and FGFR1 (Ornitz et al., 1996; MacArthur et al., 1995c; Kouhara et al., 1994) . Our results and others have found that the IIIc forms of FGFR2 and FGFR3 are not expressed in breast epithelial cells (Savangner et al., 1994; Scotet and Houssaint, 1995) . Therefore any autocrine stimulation of breast carcinoma cells by FGF8 would involve signalling through FGFR4 and possibly FGFR-1. We have shown that FGFR4 mRNA is present in the same breast cancers which were used to assess FGF8 mRNA expression. This result is consistent with other studies which showed FGFR4 mRNA to be present in breast cancer cell lines (Ron et al., 1993; McLeskey et al., 1994) . Immunohistochemical staining of normal and malignant breast tissues con®rms the retention of FGFR4 expression in breast cancer and localizes expression to the malignant epithelial cells . Therefore the possibility exists for autocrine stimulation by FGF8 in some breast carcinoma cells through the FGFR4 receptor and possibly FGFR1.
FGFR1 has been shown to have dierent signalling properties compared to FGFR-1 (Vainikka et al., 1994) . Its activation leads to weak activation of PLCg compared to FGFR1 and little phosphorylation of the adapter protein SHC was seen. Since SHC links receptor tyrosine kinases to p21ras and hence to raf and MAP kinase activation, as expected FGFR4 activation gave rise to little phosphorylation of raf and MAP kinase. FGFR4 is likely to signal through other pathways since FGFR4 is the only high anity FGF receptor able to promote membrane ruing, a motility associated change in the actin cytoskeleton (Johnston et al., 1995a) . In addition an 85 kDa serine kinase has been found to be associated with FGFR4 and may aect its signalling properties (Vainikka et al., 1996) . FGF8 has been shown to induce transformation so that it may be termed an oncogene (MacArthur et al., 1995b; Kouhara et al., 1994) . However studies showing this used NIH3T3 cells expressing FGF8. These cells will contain the IIIc forms of FGFR2 and FGFR3 which are not expressed in epithelial cells so it is possible that the transformation is mediated through receptor classes which will not be present on breast cancer cells. Other work has shown that integration of MMTV adjacent to the fgf8 gene in transgenic mice expressing wnt-1 leads to mammary carcinoma in mice suggesting that, at least in co-operation with other factors, FGF8 may transform breast epithelial cells as well (MacArthur et al., 1995a ).
This increase in the level of FGF8 in breast cancer is in marked contrast to other members of the FGF family. FGF1 and FGF2 are present at signi®cant levels in the non-malignant breast, however, a large decrease in expression of these growth factors is seen in most breast cancers (Bansal et al., 1995; Anandappa et al., 1994; Luqmani et al., 1992) . Low levels of FGF2 in breast cancer have been linked to poor prognosis (Yiangou et al., 1997a) . FGF3 and FGF4 are not detected in either malignant or non-malignant breast tissue although FGF5, 6 and 9 mRNA have been detected in breast cell lines there is no detailed data available on their levels of expression (Penault-Lorca et al., 1995) . FGF7 is present in similar amounts in both malignant and non malignant breast tissue. It is produced by the stromal ®broblasts and appears to have a paracrine role acting on the epithelial cells via it's cognate receptor FGFR2-IIIb.
FGF8 is the ®rst member of the FGF family whose expression is increased in breast cancer leading to the possibility that it plays a role in the initiation or maintenance of aspects of the malignant phenotype. Studies have demonstrated that it acts through FGFR2c, FGFR3c, FGFR4 and FGFR1 (MacArthur et al., 1995c; Ornitz et al., 1996; Blunt et al., 1997; Kouhara et al., 1994) and we have shown, by PCR and immunohistochemistry, that FGFR4 and FGFR1 are present in breast cancers allowing a potential autocrine loop to develop. If there are a proportion of breast cancers that are driven by such a loop then interrupting this cycle could lead to the development of novel therapies.
Materials and methods
Materials
Reverse transcriptase was obtained from Gibco-BRL (Paisley, UK), Taq polymerase from Peninsular Laboratories (UK), dNTPs from Pharmacia (Uppsala, Sweden). RNAzol was from Biogenesis (Bournemouth, UK). Gamma [ 32 P]ATP (370 Ci mmol 71 ) and Hybond N + membranes were from Amersham (UK). Oligonucleotides were obtained from Oswell Laboratories (Southampton, UK). FGF8 was obtained from R&D (Abingdon, UK). All other reagents were from Sigma (Poole, UK) unless otherwise indicated and were of the highest available grade.
Oligonucleotides
The primers used for PCR ampli®cation of FGF8 were: sense 5'-CACTTGCTGGTCCTCTGCCTCCAAG-3' and antisense 5-GTAGTTGAGGAACTCGAAGCG-3'. The primers for ampli®cation of FGFR-4 were:-5'-GGTCC-TGCTGAGTGTGCCTG-3' (sense) and 5'-GGGGTAA-CTGGCCTATTCG-3' (antisense). For actin PCR amplification primers 5'-CATCTCTTGCTCGAAGTCCA-3' (sense) and 5'-ATCATGTTTGAGACCTTCAA-3' (antisense) were used. The internal primers used for probing in Southern blot analysis were: 5'-GTGCACCTCGCGCT-GATGCTG-3' for FGF8, 5-CCTCACCGACCGAGCGC-GGCTACAG-3' for actin and 5'-TGGAGCAGCAAGAG-CAGGAG-3' for FGFR4.
The oligonucleotides for FGF8 were chosen from exons present in all isoforms. In addition they were chosen from areas that are unique to FGF8 and not the common FGF core (Figure 1a ).
Cell lines
Eight human mammary cell lines were used in this study along with puri®ed populations of epithelial and myoepithelial cells and ®broblasts prepared from reduction mammoplasty tissue by immunomagnetic separation . The cell lines used were MDA-MB-231, MDA-MB-415, ZR 75-1, MCF7, T47D, SKBRIII, PMC42 and HBL100. All cell lines were cultured in RPMI medium supplemented with 10% foetal calf serum, 100 units ml 71 penicillin, 100 ml 71 streptomycin and 2 mM L-glutamine. Cells were harvested at 80% con¯uence for RNA extraction.
Tissues used for RT ± PCR
Breast tissue obtained at surgery was snap frozen and stored in liquid nitrogen. We used issue from 68 malignant tumours, nine benign biopsy specimens and 15 samples of histologically normal tissue removed from adjacent to a carcinoma.
Determination of FGF8 and FGFR4 mRNA by RT ± PCR ampli®cation and Southern blotting Cellular RNA was extracted from pulverised frozen tissues using the modi®ed RNAzol method (Chomczynski and Saachi, 1987) . Semiquantitative RT ± PCR ampli®cation were performed as described previously (Luqmani et al., 1992) . Brie¯y 2 mg of RNA was reverse transcribed using random primers and cDNA was ampli®ed using 1 unit of Taq polymerase in 50 ml containing 16reaction buer (Peninsular) 1.5 mM MgCl 2 , 200 mM dNTPs, 200 ng of the FGF8 primers by sequential cycles of denaturing at 948C for 1 min, annealing at 558C for 1 min and extending at 728C for 1 min (extended to 10 min for the ®nal cycle) for 32 cycles. For FGFR4 ampli®cation 28 cycles of 1 min 958C, 1 min 508C and 1 min 728C were used. Actin primers were used for each reaction to allow comparison of expression levels. RT ± PCR was carried out for 24 cycles, denaturing at 948C for 1 min, annealing at 458C for 1 min and extending at 728C for 1 min Aliquots (20 ml) of the PCR products were electrophoresed on 2% agarose gels containing 1 mg/ml of ethidium bromide and alkali blotted overnight onto Hybond N + membrane (Luqmani et al., 1992) . To hybridize, ®lters were placed in roller bottles (Hybaid, UK) with 50 ml of a solution containing 12.5 ml of X20 SSPE 33.5 ml of double distilled water, 2.5 ml of X100 Denhardt's solution, 500 ml of 10% SDS and 1 ml of 5 mg/ml single stranded DNA and incubated for 3 h at 428C. After this time the internal oligonucleotide probe, labelled with g 32 P-ATP was added and incubation continued for a further 16 ± 20 h. Filters were then washed with 46SSPE for 15 min at room temperature, 16SSPE 15 min at 378C and 16SSC for 15 min at 428C. The ®lters were then exposed for several hours in a GS-250 Molecular Imager (Bio Rad, Hemel Hempsted, UK) and the intensity of the bands was analysed using Molecular Analyst software (BioRad, Hemel Hempsted, UK). The value of FGF8 was normalized by dividing the signal for FGF8 by that for actin. Separate blots were normalized to each other by using an arbitrary sample, which was present on every run and every blot to correct for dierences between experiments caused by gel loading, running, transfer, hybridization and times of autoradiographic exposure.
Statistical comparison of levels of expression in dierent groups of samples was using the Mann ± Whitney U-test and comparison of the numbers of samples expressing FGF8 in malignant and non-malignant tissues was using the Chi squared test.
In situ hybridization
Probe preparation A linearized Bluescript-FGF8b vector was used as template to make sense and antisense riboprobes using T7 and T3 RNA polymerases. Riboprobes were labelled with digoxigenin according to the manufacturers instructions (Boehringer Mannheim, Lewes, UK). Transcript quality was assessed by electrophoresis and sensitivity was determined by dot blots. The probes were stored at 7708C.
Tissue preparation 4 mm paran sections were cut onto charged glass slides (BDH) and baked for 1 h at 508C. They were then dewaxed and rehydrated before permeabilizing with 20 mg ml 71 of proteinase K at 378C for 30 min. They were then washed with PBS and re®xed in 4% paraformaldehyde and washed again before dehydrating. 50 ml of a hybridization mix (5 ng/ml of riboprobe, 50% deionized formamide, 26SSC, 56Denhardt's solution, 250 mg/ml of herring sperm DNA, 250 mg/ml of yeast tRNA, 5 mg/ml sodium pyrophosphate, Tris HCl 50 mM, pH 7.5 ± 7.6) was placed on each section using a Sureseal coverslip (Hybaid Ltd, Teddington, UK) and the slides were incubated at 428C overnight. The following day the slides were washed for 15 min each in 46SSC at 558C, 26SSC in 428C, and 26SSC at room temperature. The sections were then incubated at 378C for 30 min with 20 ml of 100 mg/ml RNase A (Sigma, Poole, UK), following which the coverslips were removed and the slides were washed in 16SSC at 428C and then TBS at room temperature. Blocking was carried out by placing 200 ml of TBS containing 3% BSA and 20% sheep serum over each section and incubating at room temperature for 1 h. A 1/1000 dilution of sheep anti-digoxigenin antibody (Boehringer Mannheim, Lewes, UK) was prepared in TBS containing 3% BSA and 200 ml were placed over each section before leaving them at room temperature for 30 min. The slides were then washed twice in TBS at room temperature and then NTM buer (100 mM Tris HCl, 50 mM MgCl 2 , 100 mM NaCl, pH 9.0) for 5 min at room temperature. 100 ml of NBT/BCIP solution (Boehringer Mannheim, Lewes, UK) and 1 ml of 1 M levamisole were added to 5 ml of NTM buer and 200 ml were placed over each section. The slides were then left overnight in the dark at room temperature. The following morning the slides were washed in water to stop the reaction and brie¯y stained with haematoxylin. Control tissue sections were hybridised in the presence of the sense riboprobe, in the absence of probe with RNase A digestion being carried out before hybridization.
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